PL3135286T3 - Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów - Google Patents

Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów

Info

Publication number
PL3135286T3
PL3135286T3 PL16181339.9T PL16181339T PL3135286T3 PL 3135286 T3 PL3135286 T3 PL 3135286T3 PL 16181339 T PL16181339 T PL 16181339T PL 3135286 T3 PL3135286 T3 PL 3135286T3
Authority
PL
Poland
Prior art keywords
symptoms
methods
amide derivatives
cyclic amide
treat schizophrenia
Prior art date
Application number
PL16181339.9T
Other languages
English (en)
Polish (pl)
Inventor
Remy Henri Luthringer
Lorenzo Pellegrini
Argeris Karabelas
Original Assignee
Minerva Neurosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences, Inc. filed Critical Minerva Neurosciences, Inc.
Publication of PL3135286T3 publication Critical patent/PL3135286T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0003—Two-dimensional division
    • H04L5/0005—Time-frequency
    • H04L5/0007—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
    • H04L5/001—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0016—Time-frequency-code
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/0001—Arrangements for dividing the transmission path
    • H04L5/0014—Three-dimensional division
    • H04L5/0016—Time-frequency-code
    • H04L5/0019—Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
    • H04L5/005—Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L5/00—Arrangements affording multiple use of the transmission path
    • H04L5/003—Arrangements for allocating sub-channels of the transmission path
    • H04L5/0053—Allocation of signalling, i.e. of overhead other than pilot signals
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL16181339.9T 2010-07-20 2011-07-20 Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów PL3135286T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36607510P 2010-07-20 2010-07-20

Publications (1)

Publication Number Publication Date
PL3135286T3 true PL3135286T3 (pl) 2024-04-22

Family

ID=45497166

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16181339.9T PL3135286T3 (pl) 2010-07-20 2011-07-20 Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów
PL11810349T PL2595484T3 (pl) 2010-07-20 2011-07-20 Zastosowanie cyklicznych pochodnych amidowych do leczenia zaburzeń snu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11810349T PL2595484T3 (pl) 2010-07-20 2011-07-20 Zastosowanie cyklicznych pochodnych amidowych do leczenia zaburzeń snu

Country Status (22)

Country Link
US (3) US20180155318A1 (enExample)
EP (4) EP3335731B1 (enExample)
JP (2) JP6053678B2 (enExample)
KR (1) KR101867633B1 (enExample)
CN (1) CN103220910B (enExample)
BR (1) BR112013001303A2 (enExample)
CA (2) CA2806017C (enExample)
DK (2) DK2595484T3 (enExample)
ES (2) ES2963362T3 (enExample)
FI (1) FI3135286T3 (enExample)
HR (1) HRP20231446T1 (enExample)
HU (1) HUE064157T2 (enExample)
LT (1) LT3135286T (enExample)
NO (1) NO2595484T3 (enExample)
PL (2) PL3135286T3 (enExample)
PT (2) PT3135286T (enExample)
RS (1) RS64819B1 (enExample)
RU (1) RU2576611C2 (enExample)
SI (1) SI3135286T1 (enExample)
SM (1) SMT202300413T1 (enExample)
TW (1) TWI583679B (enExample)
WO (1) WO2012012542A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301320B2 (en) * 2014-12-02 2024-11-01 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
CN113694065A (zh) * 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
GB202416895D0 (en) * 2024-11-18 2025-01-01 Phytoquest Ltd Treatment of sleep disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
EP0497843A4 (en) * 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
NZ521576A (en) * 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
JP5281395B2 (ja) * 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のglyt1阻害剤としてのシクロヘキサンスルホニル誘導体
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Also Published As

Publication number Publication date
SI3135286T1 (sl) 2024-02-29
DK3135286T3 (da) 2023-11-27
EP2595484A1 (en) 2013-05-29
BR112013001303A2 (pt) 2016-05-17
CA2806017C (en) 2021-06-29
EP4494704A2 (en) 2025-01-22
CA3117855A1 (en) 2012-01-26
RU2013107382A (ru) 2014-08-27
CN103220910B (zh) 2016-05-11
US20180155318A1 (en) 2018-06-07
SMT202300413T1 (it) 2024-01-10
EP3335731A1 (en) 2018-06-20
LT3135286T (lt) 2023-11-10
KR101867633B1 (ko) 2018-06-15
WO2012012542A1 (en) 2012-01-26
JP6053678B2 (ja) 2016-12-27
ES2963362T3 (es) 2024-03-26
PT3135286T (pt) 2023-11-28
PT2595484T (pt) 2018-01-22
RS64819B1 (sr) 2023-12-29
PL2595484T3 (pl) 2018-03-30
FI3135286T3 (fi) 2023-11-15
CA3117855C (en) 2023-01-10
EP3335731B1 (en) 2024-09-04
ES2656313T3 (es) 2018-02-26
TW201211021A (en) 2012-03-16
CN103220910A (zh) 2013-07-24
EP3135286A1 (en) 2017-03-01
JP2013531072A (ja) 2013-08-01
KR20130129905A (ko) 2013-11-29
NO2595484T3 (enExample) 2018-03-17
JP2017031159A (ja) 2017-02-09
TWI583679B (zh) 2017-05-21
JP6200561B2 (ja) 2017-09-20
EP4494704A3 (en) 2025-04-23
DK2595484T3 (en) 2018-01-22
EP3135286B1 (en) 2023-09-06
HRP20231446T1 (hr) 2024-03-01
US20250179044A1 (en) 2025-06-05
US20220274951A1 (en) 2022-09-01
CA2806017A1 (en) 2012-01-26
EP2595484B1 (en) 2017-10-18
HUE064157T2 (hu) 2024-02-28
EP2595484A4 (en) 2014-04-23
RU2576611C2 (ru) 2016-03-10

Similar Documents

Publication Publication Date Title
SG10202009963PA (en) Melanin modification compositions and methods of use
EP2539005A4 (en) ORAL PIECE AND METHODS OF USING THE SAME
ZA201308859B (en) Quinazolines as therapeutic compounds and related methods of use
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
IL227440A0 (en) Spherical support device and methods of use
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
IL221476A0 (en) Methods and compositions to treat hemorrhagic conditions of the brain
SI2683731T1 (sl) C4-monometil triterpenoidni derivati in postopki njihove uporabe
SI2523678T1 (sl) Antagonisti Wnt in postopki zdravljenja
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
ZA201405263B (en) Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2709999A4 (en) CHINAZOLIN-7-ETHER COMPOUNDS AND ITS APPLICATION
PL3400958T3 (pl) Kompozycje i metody leczenia celiakii
PT2906221T (pt) Derivados de amida e ureia de aminoalquilpiperazinas e sua utilização
LT2827883T (lt) Tfpi inhibitoriai ir jų panaudojimo būdai
PL2767282T3 (pl) Zastosowanie glutarylohistaminy w leczeniu infekcji dróg oddechowych
IL256026B (en) Treatment methods
SMT202300413T1 (it) Metodi di utilizzo di derivati di ammide ciclica per trattare schizofrenia e relativi sintomi
ZA201405265B (en) Derivatives of aza adamantane and uses thereof
EP2672968A4 (en) ECONAZOL COMPOSITION AND TREATMENT PROCEDURE THEREWITH